Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Gilead Sciences, Inc. — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.63 (market cap $2.98B), while Gilead Sciences, Inc. trades at $150.31 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 61.2× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Gilead Sciences, Inc. for 111 Days on average.
| FNGU | GILD | |
|---|---|---|
Market Cap | $2.98B | $182.40B |
Volume | 4,682,352 | 4,469,821 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $155.80 |
52-Week Low | $13.73 | $116.74 |
Typical Hold Time | 19 Days | 111 Days |
Enterprise Value | — | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.31, down 2.39% today. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETN faces significant volatility risks, having lost 87% during previous tech sector downturns according to 247 Wallst analysis from August 19, 2026.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest near-term upside potential to resistance at $37-39, the extreme volatility and concentration in mega-cap tech stocks present substantial downside risks during market corrections. Investors require high risk tolerance for this instrument.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
